Wednesday, 26 July 2017

BioLargo a Finalist for OCTANe High Tech Innovation Awar



BioLargo, Inc. President and CEO Dennis Calvert was recently interviewed by OCTANe OC, a leading innovation cluster based in Orange County, on BioLargo’s technology, its vision, and its strategy to achieve future growth. The interview was part of a comprehensive assessment for OCTANe’s High Tech Innovation Award (HTIA), a prestigious industry award that recognizes outstanding technology innovators in Orange County. 

We’re excited to announce that BioLargo has been chosen as a finalist for this year’s (2017) OCTANe HTIA award. It’s no surprise that the company was not only nominated, but also made a finalist this year – 2017 has been a year of tremendous progress for BioLargo, both technologically and commercially. Its subsidiary, Odor-No-More, signed multiple national purchasing agreements with some of the largest solid waste management companies in North America this year for its industrial odor control product CupriDyne Clean, signalling meaningful commercial traction in this large and underserved market. Clyra Medical Technologies, another BioLargo subsidiary, completed development of its iodine-based advanced wound care products and is preparing submission for its product for FDA 510(K) application in the near future. And importantly, BioLargo’s Advanced Oxidation System (AOS) made significant strides toward commercialization, with more than 35 awarded grants, 3 commercial validation trials underway and potential engineering and scale-up partners under evaluation.

BioLargo AOS being tested in the lab

Dennis P. Calvert, President & CEO of BioLargo commented, “OCTANEe is building a dynamic ecosystem in Orange County to support technology innovation like ours.   We are proud to be chosen by such a prestigious group of companies. 

Other finalists for this year’s HTIA award include well-known computer technology companies such as HyperX and D-LINK, along with innovative biotechnology, medical, and software companies. Clearly, 2017 yielded an impressive list of finalists. For a full list of OCTANe HTIA finalists, go here.

Monday, 17 July 2017

BioLargo’s Clyra Medical Subsidiary on Track to File 510K with FDA for Novel Wound Care Products



Tamarack Advisers recently published an article focused on Clyra Medical Technologies' exciting presentation at the Peter Sheehan Wound Healing: Science & Industry Conference in San Juan, Puerto Rico. 

______________________________________________________

A year and a half ago, BioLargo, Inc. (OTC: BLGO) announced that its Clyra Medical division secured financing to advance its novel wound care products.  Steve Harrison, President of Clyra Medical Technologies, then commented, "We believe this financing will provide the capital needed to help Clyra secure the regulatory approvals and launch what we believe will become a game changer for the Advanced Wound Care industry. This is a fast-growing $8 to $10 billion market in which we believe we will be able to offer better and more cost-effective solutions.”





Last month, Clyra Medical presented their breakthrough products at the 15th annual Peter Sheehan Wound Healing: Science & Industry Conference in Puerto Rico that was attended by leading wound care clinicians and researchers. We had a chance to speak with Mr. Harrison who reported, “We are highly encouraged by the overwhelming positive response from the clinical wound care experts attending the conference.  The data from the FDA pre-submission testing generated a great deal of enthusiasm among the leading clinicians and researchers at the conference.  The required pre-submission studies were conducted by Nelson Labs, an independent third party that is recognized as one of the leaders in laboratory testing for FDA submissions.”


The presentation at the conference highlighted Clyra’s advantages over existing wound care products:

  • Clyra’s hydrogel wound dressings and wound wash are highly effective and have no known antimicrobial resistance
  • GLP lab studies demonstrated sustained release and continued antimicrobial effectiveness against major organisms
  • Effective against biofilm in laboratory controlled in vivo pig studies has shown effectiveness against mature biofilm, with better results than certain prescription antimicrobial solutions
  • Non cytotoxic, non-sensitizing, and safe to human cells
  • Can easily integrate Clyra technologies into existing products and new ones in the pipeline including regenerative tissue
 
Dr. Brock Liden, DPM, a wound care expert with an extensive wound and limb salvage practice in Ohio presented the latest Clyra data to the conference. He commented “When I was introduced to the Clyra technology I was very interested to learn more. This is a complex that has been shown to impact bacteria, and show sustained activity, yet be safe to cells and the wound healing process. It may have clinical application to be used with cellular tissue products, stem cells, and growth factors with no harm to the modality. This is a significant breakthrough in the wound space. With further clinical research we may even have a modality to impact established biofilms while doing no harm to the host or the healing modalities being utilized.  As I learn more about Clyra’s technology, I feel that it has the potential to have a significant impact in wound care as well as potential in other areas of medicine”


On the flip side of their enthusiasm is that Clyra is keenly aware of the stiff competition they will face in the wound care industry.  One established competitor offering a broad line of wound care products is Smith & Nephew (NYSE: SNN).  Another is Osiris Therapeutics (NASDAQ: OSIR) that offers regenerative medicine products for difficult to treat acute and chronic wounds.

Clyra has retained Emergo, a global firm specializing in medical device regulatory consulting, to prepare its FDA filings, and reports they are on track for filing in the very near future. With the relatively short turnaround times for 510k submissions and the ongoing need for better wound care products, it is possible that Clyra’s powerful, gentle and long-lasting products may soon find themselves entering the rewarding stage of commercialization.

** Corrected Version 7-18-2017

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Flathead Business Solutions LLC, which owns tamarackadvisorsinc.com, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Flathead Business Solutions LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Flathead Business Solutions LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit http://tamarackadvisorsinc.com/legal-disclaimer/.

SOURCE: Tamarack Advisors
 
For a link to the original article go here!

Tuesday, 27 June 2017

BioLargo Signs "National Purchasing Agreements" with Three Top Waste Industry Leaders

DENVER, CO / ACCESSWIRE / June 27, 2017 / With population density and urbanization increasing around the world, the need for cost-effective industrial odor control has become an even greater priority, and the problem has largely gone unsolved by the traditional suppliers. Historically, the available solutions have not satisfied users because most products only mask foul odors with heavy fragrances rather than eliminating the odors. Leading waste handling companies have been struggling with industrial odors for decades, believing there was no cost-effective solution that truly works. The only true solution is a product that will mitigate waste-related odors by actually eliminating the odor-causing compounds, and doing so without breaking the bank. Until now, no such product has been on the market.
Recently, a new product is gaining traction among leading waste handling companies that may change the paradigm: CupriDyne® Clean Industrial Odor Eliminator, made by Odor-No-More, Inc., a subsidiary of BioLargo, Inc (BLGO). The company claims CupriDyne Clean "actually works" by eliminating odors, rather than masking them with fragrances. The product has been proven effective against the nasty odors created at all types of facilities that handle and process our trash - from the trash trucks that haul it, to the "transfer stations" that sort it, and at the landfills, composting centers, and recycling operations where it ends up. From a scientific perspective, CupriDyne Clean oxidizes odors such as hydrogen sulfide, ammonia, mercaptans, fatty acids, sulfur compounds, and VOC's (volatile organic compounds). It can even be delivered fragrance-free since it does not rely on any sort of masking strategy.
In the past few weeks BioLargo's subsidiary Odor-No-More has signed what are known as national purchasing or national supply agreements with three leading US waste handling companies; an interesting development given that they started selling the product a year ago and had since not reported major advances in sales. In an audio interview with SNNLive posted on the BioLargo blog a few weeks ago, BioLargo's president described the signing of these national agreements as breaking a "barrier to entry". According to their SEC filings the agreements do not guarantee any volume of sales, but they do put the company in the system of a large company as an approved vendor, allowing the local facilities to easily order product and get their account serviced, without having to secure payment or deal with new contracts. And, according to Calvert, the agreements allow them to approach a facility, explain the product has been reviewed and approved by corporate and been evaluated for safety, and that other company facilities are using it with success. Doing business with a larger company can have its challenges, and 'corporate approval' in agreements like these, would be a major gateway to sales in any industry. Calvert believes sales will continue to grow and have the potential to increase "significantly", calling 2017 a "breakthrough year".
In addition to the news about these national agreements, BioLargo has also recently reported additional scientific breakthroughs in its clean water treatment technology the AOS (Advanced Oxidation System), and that the company is on the verge of filing for an FDA approval for its advanced wound care products through its subsidiary Clyra Medical Technologies. In any event, the market should respond positively as sales figures climb.
In BioLargo's April 25, 2017 trade release to industry at WasteExpo 2017, it disclosed the first national agreement, with Waste Connections, Inc., a multi-billion dollar company operating in 39 states. It announced a second national agreement in an interview on May 22, and then later identified the customer as Waste Industries USA, another top 10 U.S. company. At BioLargo's annual stockholder meeting on June 19th, they announced a third arrangement with another top 10 company but refused to disclose its identity. In a recent letter to BioLargo stockholders, Calvert reported, "We are now servicing 3 of the top 10 companies in the waste handling industry," and confirmed that sales are growing.
While the waste handling industry is certainly a prolific consumer of industrial odor control products, the need for such products extends into other large industries such as wastewater treatment, livestock and poultry production, food processing, composting and more. In fact, across these industries there are over one million industrial facilities with serious and chronic odor control challenges.
U.S. Industries that generate industrial odors
  • Approximate # U.S. Operations
  • Solid waste facilities - 15,740
  • Waste to energy plants - 300
  • Cattle and calf operations - 915,000
  • Poultry farms - 233,770
  • Meat & poultry slaughtering plants - 6,278
  • Hog farms - 12,200
  • Publicly operated wastewater plants - 14,780
Total U.S. Industrial Facilities - 1,198,068
Regardless of how large the market need is, the big question is: how much of this large market can be won by a "disruptive" new product, categorically superior to competitors? BioLargo has reported in its market analyses that the facilities they target could use anywhere from $2,000 to $20,000 per month in odor control products, although weather and temperature may have an impact on the need to control odor at any one facility. Hypothetically, if CupriDyne Clean captured 10% of the market in the solid waste facilities business alone, at a gross revenue per month of $2,000 that would equate to approximately $36 million in annual sales. There's no way to know what market share they will eventually capture. Sales should be ramping up as a result of breaking through the barriers and everyone, including management, will be anxious to see the results come in. The three recent national agreements are certainly a good sign for BioLargo's commercial future.
There appear to be a few big competitors in the industrial odor control market like ProSweet by General Electric (GE), and Versene by Dow Chemical (DOW) but apparently none perform like CupriDyne® Clean.
With all the excitement surrounding these recent developments, Calvert was quick to point out in a recent meeting at LD Micro that "Odor-No-More's continued success in this market will require careful attention to product support and customer service." Calvert added, "We love our customers, we offer exceptional service and, our CupriDyne Clean Industrial Odor Eliminator actually works."
Legal Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Flathead Business Solutions LLC, which owns tamarackadvisorsinc.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Flathead Business Solutions LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Flathead Business Solutions LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit http://tamarackadvisorsinc.com/legal-disclaimer/.
SOURCE: Tamarack Advisors

widget